Truist Securities Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

Benzinga ·  11/29/2023 01:57

Truist Securities analyst Robyn Karnauskas reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment